Pan-Alexa680(ON) detected the targeted tumor (MDA-MB-468, EGFR+); however, high background and non-specific tumor uptake (3T3/HER2) are evident on Day 1 through Day 3 post injection. This evidence concerns the gene ERBB2 and neoplasm.